Tamra Wade

Increases in the number of cancer cases being diagnosed and treated likely will drive cost trends for antineoplastic enzyme inhibitors.

The proportion of Americans diagnosed with Alzheimer's disease (AD) is projected to increase almost 2-fold over the next couple of decades due to size of the Baby Boom generation compared with the total US population.